162 related articles for article (PubMed ID: 35187953)
1. Efficacy of second-line ICIs combined with TKIs among patients with metastatic renal cell carcinoma: a real-world study.
Zhang H; Chen J; Zhang X; Zhu X; Wang Z; Sun G; Liang J; Chen Y; Shen Y; Liu J; Li X; Wei Q; Liu Z; Zeng H; Shen P
Immunotherapy; 2022 Apr; 14(5):309-320. PubMed ID: 35187953
[No Abstract] [Full Text] [Related]
2. Lenvatinib with or Without Everolimus in Patients with Metastatic Renal Cell Carcinoma After Immune Checkpoint Inhibitors and Vascular Endothelial Growth Factor Receptor-Tyrosine Kinase Inhibitor Therapies.
Wiele AJ; Bathala TK; Hahn AW; Xiao L; Duran M; Ross JA; Jonasch E; Shah AY; Campbell MT; Msaouel P; Tannir NM
Oncologist; 2021 Jun; 26(6):476-482. PubMed ID: 33792094
[TBL] [Abstract][Full Text] [Related]
3. First-line dual immune checkpoint inhibitor therapies versus combination therapies comprising immune checkpoint inhibitors and tyrosine kinase inhibitors for advanced renal cell carcinoma: a comparative analysis of the effectiveness using real-world data.
Ishihara H; Omae K; Nemoto Y; Ishiyama R; Tachibana H; Nishimura K; Ikeda T; Kobari Y; Fukuda H; Yoshida K; Shimmura H; Hashimoto Y; Iizuka J; Kondo T; Takagi T
Int J Clin Oncol; 2024 Apr; 29(4):473-480. PubMed ID: 38345708
[TBL] [Abstract][Full Text] [Related]
4. Progression-free Survival After Second Line of Therapy for Metastatic Clear Cell Renal Cell Carcinoma in Patients Treated with First-line Immunotherapy Combinations.
Fitzgerald KN; Duzgol C; Knezevic A; Shapnik N; Kotecha R; Aggen DH; Carlo MI; Shah NJ; Voss MH; Feldman DR; Motzer RJ; Lee CH
Eur Urol; 2023 Mar; 83(3):195-199. PubMed ID: 36344318
[TBL] [Abstract][Full Text] [Related]
5. Acquired Hypothyroidism in Patients with Metastatic Renal Cell Carcinoma Treated with Tyrosine Kinase Inhibitors.
Wu J; Huang H
Drug Des Devel Ther; 2020; 14():3977-3982. PubMed ID: 33061302
[TBL] [Abstract][Full Text] [Related]
6. Real World Analysis of Peritoneal Metastasis From Renal Cell Carcinoma. Meet-Uro27.
Stellato M; Buti S; Maruzzo M; Bassanelli M; Bersanelli M; Napoli MD; Dionese M; Fanelli M; Filippi R; Fotia G; Galli L; Grillone F; Maffezzoli M; Maiorano BA; Nasso C; Rebuzzi SE; Lalli L; Roviello G; Sorarù M; Vincenzi B; Procopio G; Verzoni E
Clin Genitourin Cancer; 2024 Jun; 22(3):102078. PubMed ID: 38631104
[TBL] [Abstract][Full Text] [Related]
7. The prognostic significance of CDK6 expression in renal cell carcinoma treated by immune checkpoint plus tyrosine kinase inhibition.
Wang J; Zhang S; Wang Y; Zhu Y; Xu X; Guo J
Scand J Immunol; 2023 Oct; 98(4):e13304. PubMed ID: 37294700
[TBL] [Abstract][Full Text] [Related]
8. Safety and Efficacy of Second-Line TKI Plus Anti-PD1 in Metastatic Non-Clear Cell Renal Cell Carcinoma: A Real-World Study.
Huang T; Wang J; Liu R; Wei W; Liu Y; Zhang Z; Guo S; Han H; Zhou F; He L; Dong P
Clin Genitourin Cancer; 2024 Apr; 22(2):252-260.e3. PubMed ID: 38061977
[TBL] [Abstract][Full Text] [Related]
9. Association of Cabozantinib Dose Reductions for Toxicity With Clinical Effectiveness in Metastatic Renal Cell Carcinoma (mRCC): Results From the Canadian Kidney Cancer Information System (CKCis).
Graham J; Ghosh S; Breau RH; Wood L; Tanguay S; Bosse D; Lalani AK; Bhindi B; Heng D; Finelli A; Fallah-Rad N; Castonguay V; Basappa NS; Soulières D; Pouliot F; Kollmannsberger C; Bjarnason GA
Clin Genitourin Cancer; 2024 Jun; 22(3):102060. PubMed ID: 38521648
[TBL] [Abstract][Full Text] [Related]
10. Novel Risk Scoring System for Patients with Metastatic Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors.
Martini DJ; Liu Y; Shabto JM; Carthon BC; Hitron EE; Russler GA; Caulfield S; Kissick HT; Harris WB; Kucuk O; Master VA; Bilen MA
Oncologist; 2020 Mar; 25(3):e484-e491. PubMed ID: 32162798
[TBL] [Abstract][Full Text] [Related]
11. Real-World Outcomes Among US Veterans Health Administration Patients Newly Diagnosed with Metastatic Renal Cell Carcinoma and Treated with First-Line Monotherapy.
Bhanegaonkar A; Pandya S; Zheng Y; Kim R; Krulewicz S; Kasturi V; Phatak H
Adv Ther; 2021 May; 38(5):2644-2661. PubMed ID: 33866526
[TBL] [Abstract][Full Text] [Related]
12. Impact of Immunotherapy on Real-World Survival Outcomes in Metastatic Renal Cell Carcinoma.
Poprach A; Kiss I; Stanik M; Barusova T; Pospisilova L; Fiala O; Kopecky J; Richter I; Melichar B; Studentova H; Lakomy R; Holanek M; Rozsypalova A; Zemanková A; Svoboda M; Buchler T
Target Oncol; 2023 Nov; 18(6):893-903. PubMed ID: 37957520
[TBL] [Abstract][Full Text] [Related]
13. External validation of a red cell-based blood prognostic score in patients with metastatic renal cell carcinoma treated with first-line immunotherapy combinations.
Maffezzoli M; Santoni M; Mazzaschi G; Rodella S; Lai E; Maruzzo M; Basso U; Bimbatti D; Iacovelli R; Anghelone A; Fiala O; Rebuzzi SE; Fornarini G; Lolli C; Massari F; Rosellini M; Mollica V; Nasso C; Acunzo A; Silini EM; Quaini F; De Filippo M; Brunelli M; Banna GL; Rescigno P; Signori A; Buti S
Clin Exp Metastasis; 2024 Apr; 41(2):117-129. PubMed ID: 38363410
[TBL] [Abstract][Full Text] [Related]
14. Tyrosine kinase inhibitors and immunotherapy combinations in renal cell carcinoma.
Rassy E; Flippot R; Albiges L
Ther Adv Med Oncol; 2020; 12():1758835920907504. PubMed ID: 32215057
[TBL] [Abstract][Full Text] [Related]
15. Favorable Immunotherapy Plus Tyrosine Kinase Inhibition Outcome of Renal Cell Carcinoma Patients with Low CDK5 Expression.
Xu X; Wang Y; Chen Z; Zhu Y; Wang J; Guo J
Cancer Res Treat; 2023 Oct; 55(4):1321-1336. PubMed ID: 37024096
[TBL] [Abstract][Full Text] [Related]
16. Banana-shaped survival curves of metastatic renal cell carcinoma treated with first-line immune-combinations, not just a matter of "palateau".
Rebuzzi SE; Fornarini G; Signori A; Rescigno P; Banna GL; Buti S
Hum Vaccin Immunother; 2024 Dec; 20(1):2351669. PubMed ID: 38757563
[TBL] [Abstract][Full Text] [Related]
17. Planned Discontinuation of Tyrosine Kinase Inhibitor Therapy in Metastatic Renal Cell Carcinoma: Lessons for the Era of Immunotherapy.
Buchler T; Poprach A
Target Oncol; 2024 Mar; 19(2):175-180. PubMed ID: 38308662
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety analysis of a HER2-targeting antibody-drug conjugate combined with immune checkpoint inhibitors in solid tumors: a real-world study.
Zhou YX; Wang JL; Mu XL; Zhu YJ; Chen Y; Liu JY
Aging (Albany NY); 2023 Dec; 15(24):15473-15488. PubMed ID: 38147019
[TBL] [Abstract][Full Text] [Related]
19. Eosinophilic features in clear cell renal cell carcinoma correlate with outcomes of immune checkpoint and angiogenesis blockade.
Yoshida T; Ohe C; Ikeda J; Atsumi N; Ohsugi H; Sugi M; Higasa K; Saito R; Tsuta K; Matsuda T; Kinoshita H
J Immunother Cancer; 2021 Sep; 9(9):. PubMed ID: 34580162
[TBL] [Abstract][Full Text] [Related]
20. Impact of Complete Surgical Resection of Metastatic Lesions in Patients with Advanced Renal Cell Carcinoma in the Era of Tyrosine Kinase Inhibitors and Immune Checkpoint Inhibitors.
Shimizu T; Miyake M; Nishimura N; Yoshida T; Itami Y; Tachibana A; Omori C; Oda Y; Kohashi M; Tomizawa M; Onishi K; Hori S; Morizawa Y; Dotoh D; Nakai Y; Torimoto K; Tanaka N; Fujimoto K
Cancers (Basel); 2024 Feb; 16(4):. PubMed ID: 38398232
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
